Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

N.Z. Biotech Uses New Law To Recover From Financial Problems

This article was originally published in PharmAsia News

Executive Summary

New Zealand biotech ICP Biotechnology says it has taken advantage of new law to recover from financial problems. ICP Bio relies heavily on its new-proteins business, but sales were slowed by what the firm considers difficult market conditions. The "voluntary administration" law allows the firm to find a new investor that would allow ICP Bio to recaptalize, according to its chairman, Roger Gower. (Click here for more

Table

View full table

Tags:
Latest Headlines

NASDAQ Is Nice But Home Provides Comfort For Europe’s Biotechs

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

See All
UsernamePublicRestriction

Register

SC068467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By